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Abstract According to their distinct biological functions,
membrane-active peptides are generally classified as anti-
microbial (AMP), cell-penetrating (CPP), or fusion pep-
tides (FP). The former two classes are known to have some
structural and physicochemical similarities, but fusogenic
peptides tend to have rather different features and
sequences. Nevertheless, we found that many CPPs and
some AMPs exhibit a pronounced fusogenic activity, as
measured by a lipid mixing assay with vesicles composed
of typical eukaryotic lipids. Compared to the HIV fusion
peptide (FP23) as a representative standard, all designer-
made peptides showed much higher lipid-mixing activities
(MSI-103, MAP, transportan, penetratin, Pep1). Native
sequences, on the other hand, were less fusogenic (maga-
inin 2, PGLa, gramicidin S), and pre-aggregated ones were
inactive (alamethicin, SAP). The peptide structures were
characterized by circular dichroism before and after inter-
acting with the lipid vesicles. A striking correlation
between the extent of conformational change and the
respective fusion activities was found for the series of
peptides investigated here. At the same time, the CD data
show that lipid mixing can be triggered by any type of
conformation acquired upon binding, whether a-helical,
b-stranded, or other. These observations suggest that lipid
vesicle fusion can simply be driven by the energy released
upon membrane binding, peptide folding, and possibly
further aggregation. This comparative study of AMPs,
CPPs, and FPs emphasizes the multifunctional aspects of
membrane-active peptides, and it suggests that the origin of
a peptide (native sequence or designer-made) may be more
relevant to define its functional range than any given name.
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Introduction
Membrane-active peptides exhibit a fascinating repertoire
of different biological functions. Antimicrobial peptides
(AMPs) can destroy bacteria by permeabilizing their lipid
envelopes (Zasloff 2002), while cell-penetrating peptides
(CPPs) are used to transport hydrophilic cargo across
membranes without leakage (Heitz et al. 2009; Langel
2007). Fusion peptides (FPs) are generally part of larger
proteins from enveloped viruses (Blumenthal et al. 2003;
Jahn et al. 2003), yet they represent the minimally active
agent that triggers fusion between lipid vesicles in vitro
(Zheng et al. 2006). AMPs and CPPs are often cationic and
amphiphilic (Almeida and Pokorny 2009), while FPs tend
to be more hydrophobic and rich in small side chains such
as Gly and Ala (Wilson et al. 2005). From a structural point
of view, numerous AMPs and CPPs have been designed to
fold into stable amphiphilic helices or b-hairpins (Henri-
ques et al. 2006, 2007), whereas FPs are recognized by
their intrinsic conformational plasticity (Reichert et al.
2007; Zheng et al. 2006). Given the similarities between
many AMPs and CPPs, it is not surprising that inter-
changeable activities have been demonstrated for some
of them, i.e., certain AMPs can penetrate membranes, and
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some CPPs are good antibiotics (Castanho 2010; Henriques
et al. 2006, 2007; Luque-Ortega et al. 2008). In view of this
multifunctionality, the traditional nomenclature of AMPs/
CPPs is becoming blurred, and the molecular mechanisms
attributed to these ‘‘different’’ types of agents are not clear-
cut. Structural or functional similarities between AMPs/
CPPs on the one hand and FPs on the other hand are not so
obvious and need to be explored. Fusion activities of
AMPs/CPPs have only once been tested in the recent case
of the cell-penetrating peptide TAT (Yang et al. 2010).
However, all membrane-active peptides are expected to
induce considerable perturbation in the lipid bilayer upon
binding. Therefore, the question arises whether AMPs and
CPPs may in general be able to trigger membrane fusion
(Joanne et al. 2009). Here, we demonstrate by a simple
lipid mixing assay that some AMPs and many CPPs are
indeed strong membrane-perturbing agents. Among several
available methods used to monitor vesicle fusion, lipid
mixing describes the first step, leading up to at least
hemifusion. We will thus take the lipid-mixing signal as an
indication of membrane fusion—though not necessarily
involving a well-orchestrated process.
In the literature there is no unanimous agreement on the
structure of any fusogenic peptide in the membrane-bound
state. A range of different conformations has been reported
even for the most representative fusion peptide FP23 from
HIV-1, ranging from a-helix to b-sheet, mixtures thereof,
or random coil, depending on the peptide concentration,
lipid composition, and sample history (Castano and Desbat
2005; Jaroniec et al. 2005; Lorin et al. 2006; Qiang et al.
2009; Sackett et al. 2010; Sackett and Shai 2005; Zheng
et al. 2006). Such conformational plasticity seems to be
characteristic not only for FP23, but also for FPs in general
(Lorieau et al. 2010; Sun and Weliky 2009). Nevertheless,
it is important to realize that the various structural studies
were performed under different conditions, and generally
in the post-fusion equilibrium state. So it may not be sur-
prising that a recent kinetic analysis of FP23 showed that
the rate-limiting step of the actual fusion process involves
neither an a-helix nor a b-sheet, but rather an intrinsically
flexible conformation (Reichert et al. 2007), which corre-
lates well with a recent solid-state NMR analysis (Grasnick
et al. 2011). In contrast to FPs, typical AMPs and CPPs are
assumed to (or have been designed to) exhibit well-defined
conformations, such as amphiphilic a-helices. We thus
selected and compared a number of exemplary peptides
(Table 1) with supposedly different secondary structures,
such as a-helix, 310-helix, polyproline type-II helix (PPII),
b-turn, b-strand, disordered, and aggregated.
Ten representative AMPs and CPPs from different
structural families were chosen to test their potential fuso-
genic action. The AMPs include the cationic magainin-2
(Tremouilhac et al. 2006) and PGLa (Afonin et al. 2008),
which naturally occur in the skin of African frog Xenopus
laevis. The designer-made MSI-103 is an analogue of PGLa
that exhibits a higher therapeutic index (Maloy and Kari
1995; Strandberg et al. 2008). All three peptides are
unstructured in aqueous solution and fold into an amphi-
philic a-helix when bound to membranes (Burck et al. 2008;
Toke et al. 2004; Tremouilhac et al. 2006). The peptaibol
alamethicin F30/3 from the fungus Trichoderma viride
carries a single negative charge and is rather hydrophobic,
with a low solubility in aqueous buffer. In membranes it
folds into an a-helix with some 310-character, which can
self-assemble to form ion channels (Maisch et al. 2009).
Finally, the cationic gramicidin S from Bacillus brevis has
an amphiphilic cyclic structure with b-turns (Wadhwani
et al. 2006). The CPPs were selected according to their
Table 1 Investigated peptides
Peptide Type Sequence Proposed structure
FP23 FP AVGIGALFLGFLGAAGSTMGARS-NH2 a-helix, b-sheet (Qiang et al. 2007; Zheng et al. 2006)
Magainin 2 AMP GIGKFLHSAKKFGKAFVGEIMNS Amphiphilic a-helix (Maloy and Kari 1995; Tremouilhac et al. 2006)
PGLa AMP GMASKAGAIAGKIAKVALKAL-NH2 Amphiphilic a-helix (Afonin et al. 2008; Tremouilhac et al. 2006)
MSI-103 AMP KIAGKIAKIAGKIAKIAGKIA-NH2 Amphiphilic a-helix (Maloy and Kari 1995; Strandberg et al. 2008)
Alamethicin* AMP Ac-UPUAUAQUVUGLUPVUUEQF-ol a-helix, 310-helix (Maisch et al. 2009)
Gramicidin S AMP Cyclo-[PVOLf PVOLf] Cyclic with b-turns (Wadhwani et al. 2006)
Penetratin CPP RQIKIWFQNRRMKWKK a-helix (Derossi et al. 1998)
Transportan CPP GWTLNSAGYLLGKINLKALAALAKKIL-
NH2
Kinked a-helix (Lindberg et al. 2001)
MAP CPP KLALKLALKALKAALKLA-NH2 a-helix, b-aggregate (Scheller et al. 1999; Wadhwani et al. 2008)
SAP CPP VRLPPPVRLPPPVRLPPP Polyproline-II-helix (Pujals and Giralt 2008)
Pep1 CPP KETWWETWWTEWSQPKKKRKV Trp-rich (Henriques and Castanho 2004)
For sequences, lower case characters indicate D-amino acid; * U: AIB: aminoisobutyric acid; ol, alcoholic C-terminus; Ac, acetylated N-terminus
 O: ORN: ornithine after aminoisobutytic acid
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popular use in cellular delivery. Penetratin corresponds to a
fragment from the third helix of the antennapedia homeo-
domain protein, but no membrane-bound structure has been
reported (Derossi et al. 1998). Transportan, constructed
from the N-terminal part of the neuropeptide galanin and
the wasp venom mastoparan, forms a kinked a-helix in
detergent micelles (Lindberg et al. 2001). The ‘‘model
amphiphilic peptide’’ MAP had been designed as an ana-
logue of the amphiphilic a-helical AMPs described above
(Scheller et al. 1999). Under many conditions, however, it
aggregates into b-structures when membrane-bound
(Wadhwani et al. 2008). A proline-rich analogue of maize
zein, optimized for cell penetration under the name ‘‘sweet
arrow peptide’’ SAP, forms an amphiphilic PPII-helix
(Pujals and Giralt 2008). Finally, Pep1 is a Trp-rich CPP,
presumably with a flexible conformation (Henriques and
Castanho 2004). We note that many of these peptides, and
many other CCPs in general, have some tendency to
aggregate (Pujals et al. 2006).
Materials and methods
Materials
All lipids were purchased from Avanti Polar Lipids
(Alabaster, AL, USA). The lipid mixture LM3 contains
POPC, POPE, POPS, sphingomyelin, and cholesterol in a
10:5:2:2:10 molar ratio. Peptides were synthesized by
standard Fmoc solid-phase protocols on Syro II multiple
peptide synthesizer (Syro II, MultiSyntech, Germany) on a
100-lmol scale (Fields and Noble 1990). Only alamethicin
(F30) was synthesized by manual Fmoc protocols (Maisch
2008; Maisch et al. 2009). Crude peptides were purified on
C18 preparative columns using a preparative RP-HPLC
system (Jasco, Japan) and water-acetonitrile gradients
supplemented with 5 mM HCl. Purities over 95% and
peptide masses were confirmed by analytical HPLC–MS
(l-TOF, Bruker, Germany) (Afonin et al. 2003; Wadhwani
et al. 2006). Peptide stock solutions were prepared by
weighing the dry powders in cases where there the absence
of Trp in the sequence did not allow a more accurate
determination by UV/VIS absorption. According to our
experience with our self-synthesized/purified cationic
peptides, their concentrations tend to be underestimated by
up to 20% when calculated simply from the nominal molar
mass of the peptide. This error can be attributed largely to
the presence of counter-ions in the lyophilized material
after performing HPLC with acidic solvents (here: HCl).
To account for this weight contribution, all amino groups
were considered to be charged and accompanied by a
counter-ion (here: Cl-) when calculating the effective
molecular weight. Since the same stock solutions were
employed for the lipid mixing assays and the CD spec-
troscopy, any slight error in concentration does not change
the conclusions of this manuscript, i.e., that there is a
correlation between lipid perturbation and peptide folding.
Preparation of large unilamellar vesicles (LUVs)
All lipids were purchased from Avanti Polar Lipids (Ala-
baster, AL, USA) to prepare the lipid mixture ‘‘LM-3,’’
which is often used in viral fusion assays as it reflects the
lipid head group and cholesterol composition of a typical
eukaryotic target cell (Aloia et al. 1993; Yang et al. 2003).
The mixture contains POPC, POPE, POPS, sphingomyelin,
and cholesterol in a 10:5:2:2:10 molar ratio. Lipids and
cholesterol powders were co-dissolved in chloroform,
which was then removed under a gentle stream of nitrogen,
followed by overnight drying under vacuum. Lipid dis-
persions were prepared by addition of aqueous buffers
(5 mM HEPES: pH 7.0 or 10 mM phosphate: pH 7.0)
followed by vigorously vortexing (10 9 1 min) and
homogenization via ten freeze–thaw cycles. Finally, LUVs
were prepared by extrusion through a polycarbonate filter
with 100-nm diameter pores (Avanti Mini Extruder),
maintaining the temperature above 40C by thermostatting
the extruder block at 50C. The formation of the vesicles
was monitored by dynamic light scattering (DLS) (see below),
showing that the initial multilamellar vesicles with an average
diameter of about 500 nm and a broad size distribution yiel-
ded after 5–7 passes a constant diameter of 118 ± 22 nm.
Therefore, 11 passes were sufficient to yield LUVs with a
sharp size distribution to be used in all fusion and CD exper-
iments. Fusion experiments were performed with vesicles
containing fluorescent dyes conjugated to the lipid head
groups: NBD-PE (dioleoylphosphatidylethanolamine-N-7-
nitro-2-1,3-benzoxadiazole-4-yl) and Rh-PE (dioleoylpho-
sphatidylethanolamine-N-lissamine rhodamine B sulfonyl).
Lipid mixing measurements
Fusion experiments were carried out by measuring the
fluorescence intensity change resulting from the fluores-
cence resonance energy transfer (FRET) between NBD-PE
and Rh-PE inserted in the LUV bilayer (Struck et al. 1981).
Vesicles containing both dyes at 2 mol% each were mixed
with dye-free vesicles at a 1:10 molar ratio to give a final lipid
concentration of 150 lM. Fluorescence was recorded on a
spectrofluorimeter (FluoroMax2, HORIBA Yobin Yvon)
with excitation wavelength set at 450 nm and emission
wavelength at 530 nm (6-mm slit widths). To avoid cross-
talk and scattering artifacts, the emission monochromator
was shielded with two cutoff filters (GG470 and GG495,
2 mm each, Schott, Mainz, Germany). The samples (1.5 ml)
were continuously stirred, and the temperature was kept at
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37C with a thermostatic bath. The initial fluorescence of the
combined vesicles was taken as 0% lipid mixing, and the
extent of mixing was referred to the fluorescence level
20 min after addition of 2 mol% peptide, measured relative
to complete lipid mixing that was achieved by detergent
solubilization with Triton X-100. Different peptide con-
centrations were tested from 1 to 7 mol%, resulting in a
linear increase of the fluorescence signal. A concentration of
2 mol% FP23, corresponding to a peptide-to-lipid ratio of
1:50, was chosen as a suitable concentration yielding reliable
signal intensity in the usual fusion reaction time of 20 min.
All peptides, except for alamethicin, were prepared as stock
solutions in water (1 mg/ml) by weighing the lyophilized
peptide. These were added to the vesicles to give a final
peptide concentration of 3 lM, i.e., 2 mol% relative to the
amount of lipids. In the case of alamethicin the stock solution
contained 50% (v/v) trifluoroethanol (TFE) in water, which
resulted in an overall TFE content of 0.75 vol% in the sam-
ple. The influence of TFE on the stability of lipid vesicles
was independently examined by monitoring the fusion
signals of FP23 in the presence of TFE. No significant
change of the lipid mixing signals was observed up to 2 vol%
of TFE.
The peptides Pep1, penetratin, and transportan contain
Trp residues, so one has to be cautious in the data analysis
because of its known quenching effect on organic dyes
(Marme et al. 2003; Vaiana et al. 2003). We found that the
FRET assay when performed at 530 nm is indeed strongly
influenced in the case of Pep1 (5 Trp), for which only a
very small mixing signal was detectable. For penetratin (2
Trp) the mixing signal was also slightly affected, though
not for transportan (1 Trp). The ability of Pep1 to induce
vesicle fusion has been previously examined in a lipid
mixing assay by quantifying the (total) fluorescence
decrease of Rh-PE at 590 nm (Henriques and Castanho
2004). At this wavelength one observes a superposition of a
fast decrease (within 3 s) due to Pep1 binding to the ves-
icles and peptide-induced quenching of rhodamine by Trp
residues (85% of the total signal). The residual 15% of the
signal consists of an additional slow decrease within the
usual time scale of lipid mixing (10–15 min). Therefore, in
the case of Pep1 we evaluated only the observed amplitude
of the slow decrease, but at 585 nm, and referenced this
to the corresponding decrease of FP23 at the same
wavelength.
Vesicle size measurements
The size of the lipid vesicles was determined before and
after peptide-induced fusion by DLS (Zetasizer Nano S,
Malvern Instruments Ltd.), under a scattering angle of
173. Using the built-in software, the cumulant analysis
yielded the mean size (z-average diameter) of the vesicles
from the slope of the linearized form of the autocorrelation
function (first cumulant). The second cumulant was used to
calculate the polydispersity index (PdI), a parameter that
reflects the width of the size distribution. After vesicle
preparation, a z-average diameter of about 120 nm was
observed with a PdI of 0.085 ± 0.029, indicating a narrow,
nearly monomodal distribution, which remained unchan-
ged for at least 3 days when stored at 4C. The sizes of the
fused vesicles were determined 20 min after addition of
the peptides at 3 lM (2 mol%). Aliquots (500 ll) of the
samples in which lipid mixing had been induced at 37C
were transferred to the Zetasizer instrument, and the vesi-
cle mean size was characterized at 23C. However, with
some peptides the fused vesicles showed a tendency to
aggregate further up to some micrometers in diameter,
resulting in highly fluctuating scattering events and non-
analyzable DLS data. These sticky vesicular aggregates
could be readily dispersed by short sonication (15 s) in a
weak ultrasonic bath, yielding stable and reproducible
vesicle size determinations. The applicability of this
treatment was verified with FP23, since the vesicles fused
by this peptide did not change their diameter before and
after more than 10 repetitive ultrasonic treatments. The
peptides MSI-103, penetratin, and Pep1 required up to five
sonication treatments because of the high aggregation
tendency of the fused vesicles. Since the DLS-recorded
diameter kept increasing over several minutes, for these
peptides only the DLS values obtained within the first
1–2 min after fusion were taken as a reliable measure of
the fused vesicle diameters.
Circular dichroism spectroscopy
CD spectra of the peptides were acquired on a Jasco J-810
spectropolarimeter (Jasco, Tokyo, Japan) in quartz glass
cuvettes of 0.2 cm path length at 20C in 10 mM phos-
phate buffer at pH 7.0, with and without vesicles. An
average of three scans was usually recorded, and all spectra
were referenced against a peptide-free solution. Stock
solutions of peptides (1 mg/ml) and LUVs (9.6 mM) were
prepared in phosphate buffer, and the final peptide-to-lipid
molar ratio in the cuvette was 2 mol%. In the case of
alamethicin the peptide stock contained 50 vol% TFE,
yielding 2.5 vol% in the CD cuvette. To maintain a con-
stant ellipticity on the absolute scale (i.e., same number of
amide bonds), the lipid-free spectra were recorded by
adding 50 ll of peptide solution to 450 ll of phosphate
buffer, resulting in a final peptide concentration of
17–45 lM. In the presence of lipids, the peptide-to-lipid
molar ratio was kept constant at 2 mol%, and the fusion
reaction was allowed to be completed (20 min at 37C)
before recording another set of spectra at 20C. To
avoid absorbance flattening due to vesicle aggregation,
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particularly at short wavelengths, the peptide/lipid spectra
with MSI-103, penetratin, and Pep1 were recorded within
2 min after short (15 s) ultrasonic treatment of the samples,
and five spectra were averaged.
Results
The lipid mixture LM3 reflects the lipid head group
composition and cholesterol content of a typical eukary-
otic plasma membrane. It is commonly used in fusion
assays to mimic the response of eukaryotic cells (Aloia
et al. 1993; Yang et al. 2003). Peptide-induced lipid
mixing between large unilamellar LM3 vesicles was
monitored by a standard FRET assay (Aloia et al. 1993;
Reichert et al. 2007; Struck et al. 1981; Yang et al. 2003),
and DLS served as an independent measure of vesicle
size increase. To compare the AMPs and CPPs of Table 1
in a quantitative manner, each experiment was completed
by a final step of detergent solubilization with Triton
X-100, setting the 100% level as complete lipid mixing
(Reichert et al. 2007). This way, all values can be com-
pared with one another and with the activity of the des-
ignated fusion peptide FP23 of HIV-1, which is used here
as a reference standard.
The FRET experiments, induced by 2 mol% peptide
(i.e., a peptide-to-lipid molar ratio of 1:50), typically
showed a lipid mixing signal consisting of a fast
jump within 2–3 s, followed by a slow increase over
10–15 min. The jump is attributed to peptide binding,
while the amplitude of the slow component is attributed
to lipid mixing and was taken as a measure of the
extent of vesicle fusion. The data are displayed in
Fig. 1a for all peptides relative to Triton X-100, and
ranked in order of decreasing activity. Remarkably,
MAP, transportan, MSI-103, penetratin, and Pep1
exhibit a fusion activity several times higher than FP23.
The effect of the AMPs gramicidin S, magainin-2, and













































































Fig. 1 Fusogenic activities and structural properties of AMPs and
CPPs. a Lipid-mixing activities of different AMPs (red horizontal)
and CPPs (green vertical), displayed in order of decreasing activity.
The amplitudes of the fluorescence resonance energy transfer (FRET)
lipid-mixing signal are shown relative to the extent of fusion induced
by the detergent Triton X-100 (=100%). These values can be
compared to the activity of the viral fusion peptide FP23 (left
column). b Alternative assay for fusion activity based on dynamic
light scattering (DLS), which gives the increase in average vesicle
diameter (from originally 120 nm) after peptide-induced fusion.
c Circular dichroism (CD) was used to determine the extent of the
conformational change experienced by the peptides upon inducing
fusion. Here we show the absolute difference in mean residue
ellipticity (MRE) at 195 nm before and after fusion (see Fig. 2).
d Total charge of each peptide (including free termini). e Mean
residue hydrophobicity of each peptide, normalized according to the
Eisenberg consensus scale (Eisenberg et al. 1984). All experimental
values (FRET, DLS, CD data) represent the mean value of three or
more independent experiments
c
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alamethicin and SAP have no significant lipid-mixing
activity at all.
We also monitored the vesicle size increase by DLS
under the same conditions as FRET, as summarized in
Fig. 1b. Starting with an average LUV diameter of about
120 nm, the size was measured 20 min after addition of the
peptide when the lipid mixing signal had reached a plateau.
For FP23, the diameter increased from 118 ± 24 nm to
180 ± 35 nm. The results on the AMPs and CPPs show
that their ranking according to DLS follows the same order
of activity that had been established by FRET. This close
correspondence of vesicle size increase and lipid mixing
suggests that (at least hemi-) fusion has occurred in all
cases, and not just peptide-induced aggregation or lipid
perturbation.
Next, all peptide systems were characterized by circular
dichroism before and after the fusion process, to be able to
correlate the fusion activities with any observed changes in
peptide conformation. Their secondary structures were
characterized by recording CD spectra, first in 10 mM
phosphate buffer at pH 7 (dashed lines) and subsequently
in the presence of the lipid vesicles after lipid mixing had
been completed (solid lines), as shown in Fig. 2. These
experiments were performed under the same conditions as
for FRET and DLS, except that HEPES buffer was avoided
because of its strong background absorbance, and the
peptide concentration was scaled up to achieve a reason-
able signal-to-noise ratio while maintaining a peptide-to-
lipid ratio of 1:50. The changes in secondary structure are
summarized for all peptides in Fig. 1c by displaying the
Fig. 2 Conformational change upon membrane binding. CD spectra
of the peptides before fusion (dashed lines: 10 mM phosphate buffer,
pH = 7) and 20 min after inducing vesicle fusion (thick lines: LUVs
of LM3 lipid mixture). The extent of the conformational change is
illustrated by the difference spectra (dotted lines) and is indicated by
the arrows at 195 nm (where the loss of random coil signal is most
pronounced)
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difference in mean residue ellipticity at 195 nm before and
after fusion (see explanation below). Remarkably, these
data are seen to essentially follow the same order of
activity that had emerged from the fusion assays above.
Inspection of the CD lineshapes in Fig. 2 shows that
most peptides have a disordered conformation in aqueous
buffer, except for the sparingly soluble alamethicin and the
cyclic gramicidin S. Upon fusion some of the peptides
show strong conformational changes, namely FP23, MAP,
and transportan (left column), which are closely followed
by MSI-103, penetratin, and Pep1 (second column). PGLa,
magainin-2, and gramicidin S exhibit weak changes (third
column), and the CD spectra of alamethicin and SAP
remain virtually unchanged (right column). The data show
that very different types of secondary structures emerge
upon interaction with the lipids, as seen from the solid lines
in Fig. 2. FP23 attains a distinct b-conformation; MAP,
transportan, and Pep1 exhibit resembling lineshapes with
some b-stranded features, while MSI-103, penetratin,
magainin, and PGLa are similar with some a-helical fea-
tures. It would be futile to describe the resulting secondary
structures further or to perform a detailed spectral decon-
volution. This is because it is not clear whether the peptides
are 100% bound to the vesicles and assume one uniform
conformation throughout the respective sample. At this
point, we simply note that different types of secondary
structure appear to be preferred by the different membrane-
active peptides when interacting with LM3 lipid vesicles.
Despite the variations in secondary structure and pos-
sible differences in membrane affinity, we can take a look
at the extent of structural change when the peptides bind to
the vesicles. All peptides are essentially unstructured in
aqueous buffer (except for the cyclic gramicidin S, and the
pre-aggregated alamethicin and SAP), as seen from the
dashed lines in Fig. 2. It is thus justified to calculate dif-
ference spectra from the CD data from before to after
fusion, as illustrated by the dotted lines in Fig. 2. These
difference spectra typically exhibit a pronounced peak
around 195 nm, which reflects the loss of random coil
conformation upon lipid binding, irrespective of whether
any a-helical or b-stranded conformation is gained. To
express the extent of peptide folding numerically, we thus
chose to evaluate the difference in CD signal intensity at
195 nm, as illustrated by the arrows in Fig. 2. The length of
the arrow in terms of CD units is the parameter displayed in
Fig. 1c, beneath the lipid-mixing (Fig. 1a) and vesicle size
(Fig. 1b) data. Comparing these panels, it is remarkable to
see that the fusogenic activities of the diverse AMPs and
CPPs correlate in a surprisingly good manner with their CD
spectral changes. The only outlier in this series is the fusion
peptide FP23 itself. At the same time, we can clearly show
that fusion activity shows no correlation with the peptide
charge or mean residue hydrophobicity (Eisenberg et al.
1984) as illustrated below in Fig. 1d and e, respectively.
We thus conclude that peptide-induced vesicle fusion is
accompanied by and involves considerable changes in
secondary structure, and that these two aspects are directly
correlated with one another.
Discussion
Membrane fusion plays a key role in many biological
events, such as cell entry of enveloped viruses, fertilization,
vesicle trafficking, and synaptic transmission (Blumenthal
et al. 2003; Jahn et al. 2003; Ulrich et al. 1998). The fusion
process is usually mediated by protein machinery that
contains an apolar segment referred to as the fusion domain
or fusion peptide (FP). Even as isolated fragments, these FPs
are capable of inducing vesicle fusion in vitro; hence, they
are widely used as model systems to study mechanistic
aspects. At a molecular level, the fusion process involves a
massive perturbation of the membranes, leading to a com-
plete re-organization of the lipid molecules and merging of
the two apposing bilayers. Fusion peptides naturally trigger
interactions between two membranes or typically between
several vesicles in vitro. An antimicrobial or cell-penetrat-
ing peptide, on the other hand, is only supposed to interact
with a single lipid bilayer to fulfill its biological role of
causing either local rupture (by AMPs) or transient perme-
ation (by CPPs). Therefore, membrane fusion is not usually
considered to be a relevant aspect of AMP and CPP func-
tion. From a physicochemical perspective, however, it is
nonetheless clear that AMPs and CPPs also perturb the
packing of the lipid molecules and may invoke a similar
degree of membrane disruption. We therefore tested the
ability of ten different AMPs and CPPs to induce lipid
mixing among large unilamellar vesicles composed of a
typical eukaryotic LM3 mixture. Figure 1a and b demon-
strates that most CPPs (MAP, transportan, penetratin, Pep1),
as well as the man-made antimicrobial peptide MSI-103,
have potent lipid-mixing activities. Their massive fusion
effects exceed even that of the reference peptide FP23. We
may thus conclude that some AMPs and many CPPs are
capable of triggering membrane fusion in vitro. This finding
adds another complementary aspect to the previously noted
multifunctionality of membrane-active peptides. For
example, a typical cell-penetrating peptide like MAP or
transportan can apparently also exhibit fusogenic effects as
well as antimicrobial activity (Fangha¨nel 2011; Mink 2009).
The traditional nomenclature and functional distinction
between FPs and AMPs and CPPs may therefore be con-
sidered obsolete from a mechanistic point of view.
Next, the question arises as to which characteristic
features are shared by the group of highly fusogenic pep-
tides, and how they differ from the inactive ones. If a
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common denominator can be found, it might be useful for
predicting the fusogenic potential of any other amino acid
sequence. All peptides considered here are obviously
amphiphilic and possess an intrinsic affinity to bind lipid
bilayers, given their proportion of hydrophobic amino
acids. However, any simple parameters such as peptide
charge or mean residue hydrophobicity do not correlate
with their ability to trigger fusion, as seen in Fig. 1d and e.
Even some advanced concepts about membranes, such as
lipid domain formation in the LM3 mixture (which should
affect the ranking in terms of hydrophobic interactions) or
peptide-induced charge segregation of POPS (which should
affect the ranking in terms of charge), cannot therefore
explain the different behavior of the peptides. We also note
that it is futile to calculate the hydrophobic moment of a
putative folded a-helix (as had been done in Joanne et al.
2009), because the CD data show that this particular con-
formation is by no means attained by all peptides. Many of
our examples display mixed folds with a significant content
of b-strands, which are most likely attributed to non-spe-
cific aggregates. With this observation, it is clear that
fusion activity does not correlate with the actual secondary
structure of the membrane-bound peptide. Even though
this question regarding a preferred ‘‘fusogenic’’ confor-
mation has been raised in the past, it has led to rather
conflicting observations. That is, FP23 shows a-helical,
b-stranded, or mixed b-turn conformations, depending on
the lipid and sample conditions (Zheng et al. 2006). Examples
have been presented where fusion was accompanied by an
irreversible transition from an a-helical structure to an
antiparallel b-sheet (Castano and Desbat 2005). It has thus
been proposed that an intrinsic conformational plasticity is
crucial for fusion (Lorin et al. 2006). More recently, a
kinetic analysis of sterically restrained FP23 analogues has
suggested that the actual rate-determining step does not
invoke any well-defined secondary structure at all (Reichert
et al. 2007).
Our CD data show that it is not the particular type of
secondary structure that matters, but it is rather the extent
of the conformational change upon membrane binding that
correlates with the fusion activity of a peptide. The most
potent fusogenic agents (MAP, transportan) undergo the
most pronounced changes in secondary structure. Peptides
with a moderate conformational change are also able to
trigger vesicle fusion such as MSI-103, penetratin, and
Pep1, and even PGLa, magainin 2, and gramicidin S
exhibit a distinct fusion activity according to FRET. Those
peptides that are completely inactive, alamethicin and SAP,
showed no significant change in their CD spectrum upon
mixing with LM3 vesicles, as they seem to have been pre-
structured and pre-assembled already before encountering
the vesicles. The only puzzling aspect in the otherwise
excellent correlation between fusion activity and the extent
of conformational change is FP23 itself. Compared to the
dramatic conformational change observed, it exhibits a
surprisingly low fusogenic activity and has to be regarded
as an outlier. We note that even in the light of very dif-
ferent binding affinities of the various peptides to the LM3
vesicles, there is no question about the fact that we observe
a genuine correlation here between fusion activity and
conformational change. That is, consider a certain peptide
that does not bind well and will simply remain in solution.
This candidate will not only exhibit a correspondingly low
lipid mixing activity, but at the same time it would show
only a correspondingly small change in CD signal. On the
other hand, a strong binder would respond vigourously in
terms of both fusion and conformational change. We also
note that any errors in determining the accurate peptide
concentrations, which often affect the interpretation of CD
spectra, are of no concern here either, because all experi-
ments (FRET/DLS, and CD) were carried out using the
same stock solutions. And finally, one may expect that the
actual order of activities displayed in Fig. 1 is strongly
affected by the choice of the particular LM3 mixture. Any
other lipid composition may lead to a rather different
ranking, but the correlation as such between fusion and
conformational change should nevertheless be observable
in the presence of different lipids.
It is important to realize that the structural properties of
the representative AMPs and CPPs under investigation are
not as clear-cut as may commonly be assumed (see
Table 1). Only few high-resolution molecular structures
are available in the relevant membrane-bound state, and on
top of that the conformation in one lipid system may differ
from that in another type of membrane. For example, the
‘‘model amphiphilic peptide’’ MAP had been designed as
an ideal a-helix as verified experimentally under several
conditions in solution (Scheller et al. 1999). However, in
various membranes it was found to aggregate as b-sheets in
a concentration-dependent manner (Kerth et al. 2004;
Wadhwani et al. 2008), as seen here also in LM3 (Fig. 2).
Likewise, the cell-penetrating transportan folds as an
a-helix in detergent micelles, but a recent analysis in
membranes showed distinct signs of b-sheet aggregation
(Lindberg et al. 2001). In fact, it has been suggested that
CPPs may generally need to undergo a certain degree of
aggregation in order to fulfill their biological function
(Pujals et al. 2006). Such aggregation may involve b-sheets
(as in MAP and transportan), but also some other confor-
mations have been implicated (assemblies of PPII-helices
for SAP, or bundles of a- and 310-helices for alamethicin).
Even some AMPs such as PGLa and magainin have been
demonstrated to oligomerize as dimers and/or higher
oligomers, which may constitute a decisive step in their
mechanism of action (Toke et al. 2004; Tremouilhac et al.
2006). Finally, for FP23 and the influenza virus fusion
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peptide, it has been demonstrated that covalent cross-
linking and presumably aggregation accelerates membrane
fusion (Lau et al. 2004; Yang and Weliky 2003). Therefore,
it is reasonable to suppose that not only folding, but also
oligomerization helps to trigger fusion, irrespective as to
whether the peptide may end up as a well-defined a-helical
assembly or as an ill-defined b-sheet aggregate. The common
denominator appears to be the conversion of a soluble, usually
disordered form into an extensively H-bonded state, wherein
hydrophilic and hydrophobic residues are favorably posi-
tioned at the bilayer-water interface.
The driving force for membrane fusion thus appears to
be the thermodynamic consequences of peptide binding,
folding, and further oligomerization and/or aggregation as
previously noted (Bentz and Mittal 2000, 2003; Lentz et al.
2000; Russell et al. 2001). The free energy released in this
process will perturb the acyl chain packing and expose
hydrophobic lipid segments to the aqueous environment,
while water molecules are displaced from the membrane
surface. The incoming peptides thus generate many defects
and probably some negative local curvature in the bilayer
such that fusion can proceed (Cevc and Richardsen 1999;
Epand and Epand 2000; Lee et al. 2005). The postulated
lipidic morphologies such as a stalk and transmembrane
contact are neither being addressed nor questioned here
(Kozlov et al. 2010). From the peptide’s point of view the
whole process appears to be—as we may conclude now—
rather disorganized and chaotic. In the context of a well-
orchestrated proteinaceous fusion apparatus, it is generally
assumed that a transmembrane complex confines the site of
local lipid perturbation and fusion (Blumenthal et al. 2003;
Jahn et al. 2003). Once this machinery has been triggered,
the fusion peptides are released and supposedly oligomer-
ize upon contact with the opposite lipid bilayer (Qiang
et al. 2009). Given the chaotic scenario described here in
vitro, it is conceivable that also the process of bilayer
fusion in vivo might invoke some rather disorganized local
peptide structures on their way to a thermodynamically
more stable post-fusion conformation.
The energetic aspects of peptide-lipid interactions gen-
erally include electrostatic attraction between peptide and
lipid head groups, van der Waals interactions of hydro-
phobic residues with the lipid acyl chains, and the forma-
tion of H-bonds when a disordered peptide folds into a
secondary structure. In our experimental set-up, electro-
statics does not seem to play a prominent role, because the
LM3 lipid mixture contains only about 7 mol% anionic
lipid, corresponding to a nominal charge of 3.5 per peptide
(added to give a 1:50 peptide-to-lipid ratio). The total
charge of the various AMPs and CPPs ranges from zero to
?7, but shows no direct correlation with fusion activity
(Fig. 1d). Instead of charge or hydrophobicity, it is the
extent of conformational change that matters. It is obvious
that H-bonds are particularly favorable in the low dielectric
environment of a lipid bilayer. A certain number of intra-
molecular H-bonds formed within an a-helix is beneficial,
and an even higher number may be achieved in a fully
aggregated oligomeric b-sheet. This consideration may
explain why b-stranded conformations are so often
observed in membrane-bound peptides and why most of
them are probably extensively aggregated to maximize the
number of H-bonded contacts.
It has been suggested as a very general concept that the
thermodynamically most stable state of an arbitrary protein
sequence should be an aggregate, possibly with local
amyloid-like b-sheet conformation (Auer et al. 2008; Chiti
et al. 2003). While this postulate was derived for proteins
in aqueous solution, it must apply even more so to a
membraneous environment. The fact that proper protein
structures exist, despite their general tendency to aggre-
gate, has been attributed to an evolutionary selection for
non-aggregating sequences. In this context, it is important
to realize that every existing CPP sequence has been either
rationally designed or has been cut out as a fragment from a
longer protein. Therefore, it is not surprising that CPPs
have not undergone any evolutionary selection against
aggregation. Instead, one would expect that they have an
intrinsically high propensity for aggregation and can
readily convert into b-structures. The same argument also
applies to fusion peptides, as these are typically cut off
from larger protein machinery, by which they are kept
stable only in the specific environment of their binding
pocket. For antimicrobial peptides, on the other hand, the
situation is completely different. Most AMPs stem from
natural sources and must have been optimized by evolution
not to aggregate. Only the designer-made antibiotic MSI-
103 has been artificially derived from PGLa. Indeed, it is
found here to take on a significant b-strand conformation in
LM3, and correspondingly it causes much more fusion than
PGLa and magainin 2. We are therefore confident that the
fundamental difference revealed here in the behavior of
native peptides compared to man-made sequences should
serve as a general caveat in any attempt to design phar-
maceutically active peptides. Many of these products are
likely to aggregate and/or misbehave in unexpected ways
when encountering a lipid membrane. If this challenge is
not taken into account in typical antimicrobial and cell
penetration assays, a rationally optimized function might
be overridden by unwanted side effects, such as peptide-
aggregation and possibly membrane fusion.
Conclusions
In this study we examined the ability of ten representative
AMPs and CPPs to trigger membrane fusion, as monitored
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by FRET lipid-mixing and DLS vesicle size increase
assays. To our surprise we found that several of these
peptides had a much stronger activity than the designated
fusion peptide FP23 from HIV, and this activity did not
correlate with charge or hydrophobicity. Instead, CD
structure analysis before and after fusion showed that those
peptides that undergo a substantial conformational change
upon lipid binding also turn out to be the most fusogenic.
Here, the extent of change in the CD lineshape correlated
directly with the fusion activity, independently of the
resulting type of secondary structure (a-helix, b-sheet, or
mixed). These observations suggest that the driving force
for fusion is the energy released when a formerly disor-
dered, soluble peptide binds to a vesicle and acquires a
secondary structure by H-bond formation, which can be
either a well-defined fold or an aggregated state. Pre-folded
and pre-aggregated peptides, on the other hand, already
exist in a stable state and are not found to promote much
vesicle fusion. Regarding the origin of natural peptide
sequences versus designer-made ones, it is tempting to
generalize that man-made membrane-active peptides
should have a high tendency to aggregate. Provided that
they are water-soluble and have an affinity for membranes,
we expect that they should trigger vigorous fusion of lipid
vesicles.
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